Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that BELSOMRA (suvorexant) is now available
at pharmacies in the United States for the treatment of insomnia in
adults who have difficulty falling asleep and/or staying asleep.
BELSOMRA is the only orexin receptor antagonist approved for the
treatment of insomnia in the United States. Orexin is one of the many
neurotransmitters in the brain involved in promoting wakefulness, and
BELSOMRA selectively blocks orexin receptors.
Language:
English
Contact:
Merck & Co., Inc.Media:Pam Eisele, 267-305-3558orMegan Wilkinson, 267-305-6463orInvestor:Justin Holko, 908-740-1879orJoe Romanelli, 908-740-1986
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more